Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

@article{Goldstein2009StatinTA,
  title={Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.},
  author={Larry B. Goldstein and Pierre Amarenco and Justin A. Zivin and Michael Messig and Irfan Altafullah and Alfred S Callahan and Michael Hennerici and Mary Joan Macleod and H. Sillesen and Richard M Zweifler and K Michael and Angela Welch},
  journal={Stroke},
  year={2009},
  volume={40 11},
  pages={3526-31}
}
BACKGROUND AND PURPOSE Laboratory experiments suggest statins reduce stroke severity and improve outcomes. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial was a placebo-controlled, randomized trial designed to determine whether treatment with atorvastatin reduces strokes in subjects with recent stroke or transient ischemic attack (n=4731). We analyzed SPARCL trial data to determine whether treatment favorably shifts the distribution of severities of ischemic… CONTINUE READING
49 Extracted Citations
43 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 49 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 43 references

or transient ischemic attack : the Stroke Prevention by Aggressive Reduction in Cholesterol Levels ( SPARCL ) trial

  • LB Goldstein, P Amarenco, +5 authors Welch KMA
  • 2007

Similar Papers

Loading similar papers…